ABIVAX is trading 4.33% down at €84.00, with no specific company news confirmed as the cause. - On September 30, ABIVAX announced seven obefazimod abstracts for United European Gastroenterology Week, including Phase 3 ABTECT data; no connection to the current drop has been established. - The broader market backdrop is negative, but the provided index moves are smaller than 0.5% and do not clearly explain the decline.